<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Treatment of oral and esophageal candidiasis in nonpregnant adults&lt;sup&gt;[1]&lt;/sup&gt;</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Treatment of oral and esophageal candidiasis in nonpregnant adults<sup>[1]</sup></h1>
<div class="graphic"><div class="figure"><div class="ttl">Treatment of oral and esophageal candidiasis in nonpregnant adults<sup>[1]</sup></div><div class="cntnt"><table cellspacing="0"><colgroup width="10%"></colgroup> <colgroup span="3" width="30%"></colgroup> <tbody> <tr> <td class="subtitle1">Condition</td> <td class="subtitle1">Initial therapy</td> <td class="subtitle1">Alternatives for refractory disease*</td> <td class="subtitle1">Duration</td> </tr> <tr> <td><strong>Oropharyngeal</strong></td> <td> <strong>Mild:</strong><sup>¶</sup> <ul class="decimal_heading"> <li>Clotrimazole troches (10 mg orally 5 times daily); <strong>or</strong></li> <li>Miconazole mucoadhesive buccal tablets (50 mg once daily applied to the mucosal surface over the canine fossa); <strong>or</strong></li> <li>Nystatin suspension or pastilles (400,000 to 600,000 units orally 4 times daily)</li> </ul> <p class="extra_spacing_top"><strong>Moderate to severe or unresponsive to topical treatment:</strong></p> <ul class="decimal_heading"> <li>Fluconazole (200 mg orally on day 1 then 100 to 200 mg orally <span class="nowrap_whitespace">daily)<sup>Δ</sup><sup>◊</sup></span></li> </ul> </td> <td> <strong>Initial approach:</strong> <ul class="decimal_heading"> <li>Double dose of fluconazole (max 400 mg <span class="nowrap_whitespace">daily)<sup>◊</sup></span></li> </ul> <p class="extra_spacing_top"><strong>If no response after several days, switch to alternative agent:</strong></p> <ul class="decimal_heading"> <li>Itraconazole oral solution (200 mg daily); <strong>or</strong></li> <li>Posaconazole oral suspension (400 mg 2 times daily for 3 days then 400 mg once daily); <strong>or</strong></li> <li>Voriconazole (200 mg orally twice daily); <strong>or</strong></li> <li>Amphotericin B deoxycholate oral <span class="nowrap_whitespace">suspension<sup>§</sup></span></li> <li>Echinocandins or IV amphotericin B can also be used as treatment for refractory oropharyngeal disease, but these are rarely indicated</li> </ul> </td> <td>Duration of treatment is 7 to 14 days for uncomplicated disease. For refractory disease, the duration is usually extended to 14 to 28 days.</td> </tr> <tr> <td><strong>Esophageal</strong></td> <td> <strong>Preferred (regardless of disease severity):</strong> <ul class="decimal_heading"> <li>Fluconazole (400 mg orally or IV on day 1 then 200 to 400 mg <span class="nowrap_whitespace">daily)<sup>Δ</sup></span></li> </ul> <p class="extra_spacing_top"><strong>Alternatives for initial therapy:</strong><sup>◊</sup></p> <ul class="decimal_heading"> <li>An IV <span class="nowrap_whitespace">echinocandin;<sup>¥</sup></span> <strong>or</strong></li> <li>Lipid formulation of amphotericin B (3 mg/kg IV <span class="nowrap_whitespace">daily)<sup>‡</sup></span></li> </ul> </td> <td> <strong>Initial approach:</strong> <ul class="decimal_heading"> <li>Double dose of fluconazole (max 800 mg <span class="nowrap_whitespace">daily)<sup>◊</sup></span></li> </ul> <p class="extra_spacing_top"><strong>If no response after several days, switch to alternative agent:</strong></p> <ul class="decimal_heading"> <li>Itraconazole oral solution (200 mg daily); <strong>or</strong></li> <li>Posaconazole oral suspension (400 mg twice daily); Posaconazole delayed-release tablet (300 mg once daily); <strong>or</strong></li> <li>Voriconazole (200 mg orally or IV twice daily); <strong>or</strong></li> <li>Isavuconazole;<sup>†</sup> <strong>or</strong></li> <li>An IV <span class="nowrap_whitespace">echinocandin;<sup>¥</sup></span> <strong>or</strong></li> <li>Lipid formulation of amphotericin B (3 mg/kg IV <span class="nowrap_whitespace">daily)<sup>‡</sup></span></li> </ul> </td> <td>Duration of therapy is 14 to 21 days for initial treatment. For refractory disease, the duration is extended to 28 days.</td> </tr> </tbody></table></div><div class="graphic_lgnd">This table should be used in conjunction with UpToDate content on treatment of oropharyngeal and esophageal candidiasis.</div><div class="graphic_footnotes"><p>IV: intravenous.</p>
<p>* Additional evaluation (eg, resistance testing) may be needed for patients with refractory disease.</p>
<p>¶ For most patients with mild disease, we prefer topical therapy; clotrimazole troches or miconazole mucoadhesive buccal tablets appear to be more effective than nystatin. However, oral fluconazole (200 mg loading dose, followed by 100 to 200 mg daily for 7 to 14 days) can be used for initial therapy if a patient cannot use troches or suspension because of the possibility of aspiration or being unable to follow directions or is at risk for disseminated disease due to severe mucosal breakdown.</p>
<p>Δ Fluconazole is generally the preferred treatment for moderate to severe oropharyngeal disease and esophageal disease. Although other oral azoles (eg, itraconazole oral solution, posaconazole suspension, voriconazole) are also effective for initial therapy, we prefer fluconazole due its ease of administration, low side effect profile, low risk of drug interactions, and cost.</p>
<p>◊ On rare occasion, when a patient has infection due to <em>Candida glabrata</em> or <em>Candida krusei</em>, fluconazole is typically not effective, and treatment with an alternative agent is required.</p>
<p>§ Amphotericin B deoxycholate oral suspension is not a commercially available product in the United States. The dose is 500 mg of an extemporaneously compounded 100 mg/mL suspension 3 to 4 times <span class="nowrap_whitespace">daily.<sup>[2]</sup></span> Patients should swish in the mouth and retain for as long as possible (several minutes) before swallowing.</p>
<p>¥ Our preferred dosing of echinocandins in adults with esophagitis is as follows: anidulafungin 200 mg IV daily; caspofungin 70 mg daily; or micafungin 150 mg IV daily. These doses are higher than those used for candidemia since there are higher rates of relapse with echinocandins than with azoles when used for the treatment of <em>Candida</em> esophagitis. However, some experts use lower doses of anidulafungin and <span class="nowrap_whitespace">caspofungin.<sup>[3]</sup></span></p>
<p>‡ Lipid formulations of amphotericin are generally preferred over the deoxycholate formulation because the risk of toxicity is reduced. However, if lipid formulations are not available and amphotericin B deoxycholate is used, the dose is 0.3 to 0.7 mg/kg IV daily.</p>
† There is no standard dosing of isavuconazole for treatment of <em>Candida</em> esophagitis; oral options include: 744 mg isavuconazonium orally as a single dose, then 186 mg isavuconazonium orally once daily <strong>or</strong> 744 mg isavuconazonium orally once weekly.</div><div class="graphic_reference">References:
<ol>
<li>Pappas PG, Kauffman CA, Andes D, et al. Clinical practice guidelines for the management of candidiasis: 2016 update by the Infections Diseases Society of America. Clin Infect Dis 2016; 62:e1.</li>
<li>Fichtenbaum CJ, Zackin R, Rajicic N, et al. Amphotericin B oral suspension for fluconazole-refractory oral candidiasis in persons with HIV infection. Adult AIDS Clinical Trials Group Study Team 295. AIDS 2000; 14:845.</li>
<li>Panel on Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. National Institutes of Health, Centers for Disease Control and Prevention, and the HIV Medicine Association of the Infectious Disease Society of America. <a href="https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf" target="_blank">https://clinicalinfo.hiv.gov/sites/default/files/guidelines/documents/adult-adolescent-oi/guidelines-adult-adolescent-oi.pdf</a> (Accessed on December 8, 2022).</li>
</ol></div><div id="graphicVersion">Graphic 86676 Version 7.0</div></div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
